News

The province of Ontario has listed ALBRIOZA on the public formulary as a therapy accessible through the Ontario Drug Benefit Program’s Exceptional Access Program (EAP) as a treatment for ALS. This decision comes quickly after the conclusion of the pCPA…

Updated on November 27, 2023 June 15, 2023 – Amylyx and the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully concluded negotiations for ALBRIOZA and entered into a Letter of Intent (LOI) for the terms and conditions under which ALBRIOZA would qualify…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

With admiration and gratitude, the ALS Society of Canada (ALS Canada) acknowledges the incredible contribution of our Board member, Dr. Christine Vande Velde, whose term has come to an end.     Dr. Vande Velde leaves her position on the Board…

The ALS Society of Canada (ALS Canada) is pleased to welcome Dr. Chantelle F. Sephton from Quebec and Craig Storey from Prince Edward Island to our Board of Directors. ALS Canada’s Board of Directors is comprised of volunteers from diverse…

Today the ALS Society of Canada (ALS Canada) recognizes the start of ALS Awareness Month across the country. Join us as we raise awareness for amyotrophic lateral sclerosis (ALS), a devastating disease that affects nearly 4,000 Canadians currently diagnosed and…

Celebrating ALS community member Kevin Daly, a new bursary of $2,500 supports the financial needs of post-secondary students Toronto, ON – In partnership with the friends and colleagues of ALS community member Kevin Daly, the ALS Society of Canada (ALS Canada) is pleased…

On April 25, 2023, the U.S. Food and Drug Administration (FDA) approved Qalsody (tofersen) for the treatment of SOD1-ALS under the Accelerated Approval pathway. On May 30, 2024, the European Commission (EC) has granted marketing authorization for Qalsody (tofersen) under…